
Kadcyla and Opdivo Too Expensive for NICE
NICE rejects promising oncology agents once again, citing high drug cost.
Two drugs that have offered hope to advanced breast cancer and advanced non-small cell lung cancer (NSCLC) patient have been rejected by the advisory watchdog to UK’s National Health Service, the National Institute for Health and Care Excellence. Nivolumab (Opdivo), manufactured by Bristol-Myers Squibb, and trastuzumab emtansine (Kadcyla), manufactured by Roche, have both received a thumbs down by NICE.
In a draft guidance,
A similar fate was established for trastuzumab emtansine.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.